Analogies for Protagonist Therapeutics (PTGX)

• Like a specialized biotech company such as Amgen, but focused on developing peptide-based drugs for blood and inflammatory disorders.
• An emerging biopharmaceutical company, similar to an early-stage Vertex Pharmaceuticals, but concentrating on treatments for blood disorders and inflammatory bowel disease.

• rusfertide (PTG-300): An injectable hepcidin mimetic in clinical trials for treating blood disorders such as polycythemia vera and hereditary hemochromatosis.
• PN-943: An oral, alpha-4-beta-7 integrin-specific antagonist peptide undergoing clinical trials for the treatment of inflammatory bowel disease (IBD).
• PN-235: An orally delivered interleukin-23 receptor specific antagonist in development for inflammatory bowel disease (IBD) and other related indications.

Protagonist Therapeutics (PTGX) is a biopharmaceutical company focused on drug discovery and development. Based on the provided information, the company's major customer at this stage is:

• Janssen Biotech, Inc.

Protagonist Therapeutics has a license and collaboration agreement with Janssen Biotech, Inc., which is a typical revenue-generating arrangement for a biopharmaceutical company in the development stage, where the larger partner often provides funding, milestone payments, and/or royalties for the development and commercialization of therapeutic drugs.

1. PolyPeptide Laboratories (U.S.) LLC (PolyPeptide Group AG - PPGN)
2. Lonza (Walkersville, Inc.) (Lonza Group AG - LONN)
3. Cerbios-Pharma SA

Dinesh V. Patel, Ph.D. President and Chief Executive Officer

Dr. Patel has served as President and Chief Executive Officer of Protagonist Therapeutics since December 2008, bringing over 38 years of executive, entrepreneurial, and scientific experience in the pharmaceutical, biotechnology, and biopharmaceutical industries. Prior to Protagonist, he was President and CEO of Arête Therapeutics, a privately held company, from 2006 to 2008. He also co-founded and served as CEO of Miikana Therapeutics from 2003 until its acquisition by Entremed (later CASI Pharmaceuticals) in 2005. Dr. Patel held various positions at Versicor (later Vicuron), which was acquired by Pfizer in a $1.9 billion transaction in 2005, and where his R&D efforts led to two marketed drugs. He also worked at Affymax and Bristol-Myers Squibb.

Asif Ali Executive Vice President, Chief Financial Officer

Mr. Ali joined Protagonist Therapeutics as Executive Vice President and Chief Financial Officer in April 2022. Before this role, he was the Chief Accounting Officer at Theravance Biopharma, where his responsibilities included overseeing various departments such as financial planning and analysis, taxation, accounting, and financial reporting. At Theravance, he was involved in raising $130 million in equity financing in February 2020 and an additional $115 million in June 2021. Earlier in his career, Mr. Ali was the Vice President and Corporate Controller at Depomed, Inc., where he played a role in supporting five product launches, four successful product acquisitions, and a significant financing event from the sale of future royalties.

Arturo Molina, M.D., M.S., F.A.C.P. Chief Medical Officer

Dr. Molina joined Protagonist Therapeutics as Chief Medical Officer in November 2022. He previously served for five years as Chief Medical Officer at Sutro Biopharma. Before Sutro, Dr. Molina was Vice President, Oncology Scientific Innovation at Johnson & Johnson. His earlier experience includes serving as Chief Medical Officer at Cougar Biotechnology, which was acquired by Johnson & Johnson in 2009.

Ashok Bhandari, Ph.D. Executive Vice President & Chief Discovery Officer

Dr. Bhandari has served as Executive Vice President & Chief Discovery Officer since January 2022, having previously held positions as Senior Vice President and Vice President of Chemistry and Process Research from 2017 to 2021. He joined Protagonist in 2011 as Director of Chemistry, focusing on the discovery of novel peptide therapeutics for the company's clinical pipeline. Prior to joining Protagonist, Dr. Bhandari spent 14 years at Affymax, from 1994 to 2008, where he worked on various peptide drug discovery, preclinical, and clinical development programs.

David Y. Liu, Ph.D. Chief Scientific Officer, Head of Research & Development

Dr. Liu has served as Chief Scientific Officer of Protagonist Therapeutics since May 2013, expanding his role to Chief Scientific Officer and Head of Research and Development in February 2016. He was a co-founder and Chief Operating Officer of Trenovus, Inc., from 2010 to 2012. Before Trenovus, Dr. Liu was Vice President of Research at FibroGen Inc., from 2002 to 2010. From 1992 to 2002, he was Director of Inflammation Research at Scios, Inc., which is now part of Johnson & Johnson.

Here are the key risks to Protagonist Therapeutics (PTGX):

1. Clinical Trial Failure and Regulatory Approval Risk: As a biopharmaceutical company with multiple drug candidates in clinical development, including rusfertide (PTG-300), PN-943, and PN-235 (also referred to as icotrokinra or JNJ-2113), Protagonist Therapeutics faces significant inherent risks associated with the successful completion of clinical trials and obtaining regulatory approvals. Drug candidates, even those in advanced stages like Phase II and Phase III, may fail to demonstrate adequate efficacy or safety, leading to delays or outright termination of development. For instance, rusfertide previously experienced a clinical hold due to a non-clinical finding, and an earlier drug candidate, PTG-100, failed a Phase 2b study on a futility analysis. Any setbacks in these processes can substantially impact the company's financial position and growth prospects.
2. Intense Competition: The biopharmaceutical industry is highly competitive, with numerous companies, including larger ones with greater resources, developing innovative therapies for similar indications. Protagonist Therapeutics' pipeline candidates, such as rusfertide for polycythemia vera and icotrokinra for psoriasis, operate in markets with existing treatments and emerging therapies. Should competing drugs demonstrate superior efficacy, safety, or achieve more favorable pricing, it could challenge Protagonist Therapeutics' market position and limit the commercial success of its products.
3. Reliance on Collaboration Partners and Limited Commercialization Experience: Protagonist Therapeutics has entered into significant collaborations with partners like Janssen Biotech, Inc. (Johnson & Johnson) for icotrokinra (JNJ-2113) and Takeda Pharmaceuticals for rusfertide. While these partnerships provide substantial capital, resources, and shared development responsibilities, they also introduce risks. The company's future success is partially dependent on its partners' commitment to continuing development and their ability to successfully commercialize any approved products. Furthermore, as a clinical-stage company, Protagonist Therapeutics has limited direct experience in drug commercialization. This could present challenges in marketing and selling products if they receive regulatory approval, potentially requiring continued reliance on partners or a significant investment in building its own commercial infrastructure, which could affect profitability and control.

Protagonist Therapeutics (PTGX) develops peptide-based therapeutic drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. The addressable markets for its main products are as follows:

Rusfertide (PTG-300)

• Polycythemia Vera: The total market size for Polycythemia Vera in the 7 Major Markets (7MM), which include the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, is approximately USD 2.0 billion in 2025 and is projected to increase through 2036. The United States market alone for Polycythemia Vera was approximately USD 1.5 billion in 2025. Approximately 150,000 patients are affected by Polycythemia Vera in the U.S., with a similar prevalence in Europe, representing an estimated market opportunity of approximately USD 1-2 billion per year across the U.S. and Europe.
• Hereditary Hemochromatosis: The global hereditary hemochromatosis treatment market size was valued at approximately USD 1.70 billion in 2025 and is expected to reach about USD 2.59 billion by 2032. Another estimate indicates the global market size was USD 1.81 billion in 2024 and is expected to reach USD 2.43 billion by 2032. Approximately one million people in the United States have HFE mutations consistent with type 1 hemochromatosis, with 10-15% developing clinical manifestations of the disease.

PN-943

• Inflammatory Bowel Disease (IBD) (specifically Ulcerative Colitis): The global Inflammatory Bowel Disease therapeutics market was valued at approximately USD 21.8 billion in 2024 and is projected to grow to USD 30.7 billion by 2034. Other estimates indicate the global IBD treatment market is forecast to expand from USD 24.8 billion in 2024 to USD 37.1 billion by 2030, or was valued at USD 29.57 billion in 2025 and is projected to grow to USD 41.64 billion by 2034. Ulcerative Colitis, which PN-943 specifically targets, represented USD 10.91 billion of the global IBD market in 2024.

PN-235

• Inflammatory Bowel Disease (IBD): The global Inflammatory Bowel Disease therapeutics market was valued at approximately USD 21.8 billion in 2024 and is projected to grow to USD 30.7 billion by 2034. Other estimates indicate the global IBD treatment market is forecast to expand from USD 24.8 billion in 2024 to USD 37.1 billion by 2030, or was valued at USD 29.57 billion in 2025 and is projected to grow to USD 41.64 billion by 2034.
• Psoriasis: The global psoriasis treatment market size was estimated at USD 29.27 billion in 2023 and is expected to reach approximately USD 68.24 billion by 2033. Another estimate values the global market at USD 28.1 billion in 2024, growing to USD 68.4 billion by 2034. In 2024, the market size for psoriasis in the 7 Major Markets (7MM) was USD 33.4 billion, with the United States accounting for approximately 80% of this total. The U.S. psoriasis treatment market was valued at USD 10.4 billion in 2024. The North America psoriasis therapeutics market size was valued at USD 10.6 billion in 2022 and is estimated to reach USD 23.3 billion by 2032.

Expected Revenue Growth Drivers for Protagonist Therapeutics (PTGX) Over the Next 2-3 Years

Protagonist Therapeutics (PTGX) is poised for potential revenue growth over the next two to three years, primarily driven by the advancement and commercialization of its key pipeline assets and the financial benefits from its strategic collaborations. The company's future revenue streams are anticipated to stem from the following areas:

1. Commercialization of Rusfertide for Polycythemia Vera: Protagonist Therapeutics, in collaboration with Takeda Pharmaceuticals, recently saw the U.S. Food and Drug Administration (FDA) accept a New Drug Application (NDA) for rusfertide, granting it Priority Review for the treatment of polycythemia vera. The NDA submission occurred in December 2025, and the FDA's acceptance for priority review in March 2026 suggests a potential market launch within the next 2-3 years. Successful commercialization of this first-in-class hepcidin mimetic is expected to be a significant driver of product sales revenue.
2. Milestone and Royalty Payments from JNJ-2113 (formerly PN-235) through Janssen Collaboration: The collaboration with Janssen Biotech, Inc. for JNJ-2113 (formerly PN-235), an oral interleukin-23 receptor antagonist, is expected to generate substantial revenue through milestone payments and future royalties. JNJ-2113 is advancing into Phase 3 clinical development for psoriasis and a Phase 2b study for ulcerative colitis, with NDA submissions anticipated around 2025. Protagonist is eligible for significant development and sales milestone payments (up to an additional $795 million) and tiered royalties ranging from 6% to 10% on worldwide net sales, which would contribute to revenue growth within the forecast period.
3. Potential Opt-Out of Rusfertide Profit Share with Takeda: Protagonist's management expects to opt out of the 50/50 profit and loss sharing arrangement for rusfertide with Takeda in the second quarter of 2026. Should this occur, Protagonist would become eligible to receive additional cash payments of up to $400 million, enhanced milestone payments potentially reaching $975 million, and royalties on worldwide net sales, rather than sharing profits and losses in the U.S. This strategic move could substantially boost the company's revenue.
4. Expansion of Rusfertide to New Indications: While the initial focus for rusfertide is polycythemia vera, the drug is also in development for hereditary hemochromatosis and other blood disorders. Successful approval and market penetration in polycythemia vera could pave the way for accelerated development and potential launches in these additional indications within the 2-3 year timeframe, expanding the drug's addressable market and revenue potential.

Share Issuance

• Protagonist Therapeutics completed an underwritten public offering of 5,000,000 shares of common stock, raising approximately $107.8 million. It also utilized an 'at-the-market' offering facility to sell shares, generating $24.3 million in net proceeds. Additionally, the company received $34.4 million in proceeds from exercising warrants in exchange for pre-funded warrants.
• In June 2021, the company closed a public offering of 3,503,311 shares of common stock, resulting in aggregate gross proceeds of approximately $132.2 million. [cite: 6 (from first search), 15]
• In June 2024, stockholders approved an amendment to increase the number of authorized common stock shares from 90,000,000 to 180,000,000, and total authorized shares from 100,000,000 to 190,000,000.

Inbound Investments

• Protagonist Therapeutics entered into a worldwide license and collaboration agreement with Takeda Pharmaceuticals for rusfertide, which included a $300 million upfront payment. [cite: 1 (from first search), 4]
• The company earned $165.0 million in milestone payments during the fourth quarter of 2024 under its icotrokinra license and collaboration agreement with Johnson & Johnson. [cite: 1 (from first search), 4]
• A $25.0 million milestone payment from Takeda was received in September 2025, related to the rusfertide agreement. [cite: 1 (from first search), 4]

Outbound Investments

• Protagonist Therapeutics has not made any investments or acquisitions. [cite: 6 (from first search)]

Capital Expenditures

• Capital expenditures were $1.6 million for the year ended December 31, 2025.
• For the year ended December 31, 2024, capital expenditures amounted to $1.4 million.
• Capital expenditures were $0.6 million for the year ended December 31, 2023. The primary focus of these expenditures is to fund operating expenses, including research and development and general and administrative costs.